<DOC>
	<DOCNO>NCT00003561</DOCNO>
	<brief_summary>RATIONALE : Interferon alfa may interfere growth cancer cell . Colony-stimulating factor sargramostim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect therapy . Combining sargramostim interferon alfa may kill cancer cell . PURPOSE : Phase II trial study effectiveness sargramostim treat patient receive interferon alfa chronic phase chronic myelogenous leukemia remission .</brief_summary>
	<brief_title>Interferon Alfa Plus Sargramostim Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Estimate rate major cytogenetic response sargramostim ( GM-CSF ) interferon alfa patient newly diagnose chronic phase chronic myeloid leukemia . II . Estimate dosing , schedule , toxic effect GM-CSF plus interferon alfa patient . OUTLINE : All patient hematologic remission subcutaneous interferon alfa upon enter study . Once complete hematologic response achieve interferon alfa dose stable 14 day , patient receive subcutaneous sargramostim ( GM-CSF ) daily 6 month . Patients follow 3 , 6 , 9 , 12 month . PROJECTED ACCRUAL : Approximately 48 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cytogenetically molecularly proven chronic phase chronic myeloid leukemia ( CML ) Philadelphia chromosome positive OR Philadelphia chromosome negative evidence BCRABL rearrangement evidence P120 protein On interferon alfa therapy le 6 month In complete hematologic response , define : WBC le 10,000/mm3 Platelet count less 450,000/mm3 Less 5 % circulate blast No sign symptom disease , include progressive splenomegaly PATIENT CHARACTERISTICS : Age : 18 Performance status : Not specify Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Not specify Renal : Not specify Other : Not pregnant nursing Fertile patient must use effective contraception No history intolerance sargramostim ( GMCSF ) Must able perform self injection PRIOR CONCURRENT THERAPY : Biologic therapy : Prior interferon alfa require Chemotherapy : Prior hydroxyurea cytarabine allow Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No concurrent myelosuppressive drug therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
	<keyword>Philadelphia chromosome negative chronic myelogenous leukemia</keyword>
</DOC>